Table 2 rhEPO protected very preterm infants against NEC
NEC | Control n/total (%) | rhEPO n/total (%) | p-value | Total n/total (%) |
|---|---|---|---|---|
Stage I | 75/644 (11.6) | 59/641 (9.2) | 0.152 | 134/1285 (10.4) |
Stage II | 25/644 (3.9) | 15/641 (2.3) | 0.112 | 40/1285 (2.3) |
Stage III | 10/644 (1.6) | 4/641 (0.6) | 0.109 | 14/1285 (1.1) |
Stage II and III | 35/644 (5.4) | 19/641 (3.0) | 0.027 | 54/1285 (4.2) |
Stage I, II and III | 110/644 (17.1) | 77/641 (12.0) | 0.010 | 187/1285 (14.6) |